This study found that men with benign prostate hyperplasia showed increased meibomian gland dysfunction and tear film instability compared to age-matched controls, and were also more likely to have androgenic alopecia.
1 citations
,
August 2022 in “Veterinary medicine and science” This review discusses various diagnostic and treatment strategies for canine prostate diseases, including pharmacological options and advanced procedures, but reports no new clinical results.
November 2021 in “Pharmaceutical Sciences” This study found that the compound androstane-17-carboxamide 6 may serve as a lead for new drugs to treat BPH and prostate cancer by reducing the weight of androgen-dependent glands.
September 2020 in “Current Enzyme Inhibition” In this study, researchers found that steroidal 17β-carboxamides 1-4 significantly inhibited 5α-reductase enzyme activity and reduced prostate weight more effectively than finasteride in a hamster model, without toxic side effects, suggesting potential for treating benign prostatic hyperplasia.
January 2018 in “Universidad Privada Antenor Orrego” This study found that androgenic alopecia may serve as an early marker for benign prostatic hyperplasia.